Read by QxMD icon Read


Eden Rebecca Padayachee, Henry Ademola Adeola, Jennifer Catherine Van Wyk, Fleury Augustine Nsole Biteghe, Shivan Chetty, Nonhlanhla Patience Khumalo, Stefan Barth
Background: Cancer treatment in the 21st century has seen immense advances in optical imaging and immunotherapy. Significant progress has been made in the bioengineering and production of immunoconjugates to achieve the goal of specifically targeting tumors. Discussion: In the 21st century, antibody drug conjugates (ADCs) have been the focus of immunotherapeutic strategies in cancer. ADCs combine the unique targeting of monoclonal antibodies (mAbs) with the cancer killing ability of cytotoxic drugs...
February 2019: Health Science Reports
Mohammad R Siddiqui, Reema Railkar, Thomas Sanford, Daniel R Crooks, Michael A Eckhaus, Diana Haines, Peter L Choyke, Hisataka Kobayashi, Piyush K Agarwal
Bladder cancer (BC) is heterogeneous and expresses various cell surface targets. Photoimmunotherapy (PIT) involves monoclonal antibodies (MAbs) conjugated to a photoabsorber (PA), IR Dye 700Dx, and then activated by near infra-red light (NIR) to specifically target tumors. We have demonstrated that tumors expressing EGFR can be targeted with PIT. However, PIT may be less effective when a tumor lacks "overwhelming" expression of a single target such as EGFR. We present a combinatorial PIT approach for targeting BC expressing EGFR and HER2, using PA- labeled panitumumab (pan) and trastuzumab (tra), respectively...
February 14, 2019: Scientific Reports
Hisataka Kobayashi
Near infrared photoimmunotherapy(NIR-PIT)is a new molecularly-targeted cancer photo-therapy based on conjugating a near infrared silica-phthalocyanine dye, IRDye700DX(IR700), to a monoclonal antibody(mAb)targeting cell-surface molecules. NIR-PIT targetingEGFR usingthe cetuximab-IR700 conjugate is now in transition to fast-track global Phase Ⅲ clinical trial in late-stage head and neck squamous cell cancer patients. When exposed to NIR light, the conjugate induces a highlyselective necrotic/immunogenic cell death(ICD)only in target-positive, mAb-IR700-bound cancer cells...
January 2019: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Jeroen Meulemans, Pierre Delaere, Vincent Vander Poorten
PURPOSE OF REVIEW: To identify and review the recent literature on clinical applications, outcome, and new developments in photodynamic therapy (PDT) for the treatment of head and neck cancer. RECENT FINDINGS: Although PDT and surgery have a similar local control and recurrence rate, the gold standard of treatment for early-stage oral cavity cancer remains local surgery with, on indication, concurrent treatment of the neck. PDT proves its value in treatment of patients with field cancerization and patients with superficial recurrence after previous surgery and/or radiation, in whom surgical salvage would entail important morbidity...
April 2019: Current Opinion in Otolaryngology & Head and Neck Surgery
Tadanobu Nagaya, Jay Friedman, Yasuhiro Maruoka, Fusa Ogata, Shuhei Okuyama, Paul E Clavijo, Peter L Choyke, Clint Allen, Hisataka Kobayashi
Near-infrared photoimmunotherapy (NIR-PIT) induces immunogenic cell death, but has mostly failed to induce durable antitumor responses in syngenic tumor mouse models. We hypothesized that adaptive immune resistance could be limiting durable responses after treatmemt with NIR-PIT. We investigated the effects of combining NIR-PIT targeting cell surface CD44 and PD-1 blockade in multiple syngeneic tumor models. In two of three models, NIR-PIT monotherapy halted tumor growth, enhanced dendritic cell tumor infiltration, and induced de novo tumor antigen-specific T-cell responses absent at baseline...
January 25, 2019: Cancer Immunology Research
Winn Aung, Atsushi B Tsuji, Aya Sugyo, Hiroki Takashima, Masahiro Yasunaga, Yasuhiro Matsumura, Tatsuya Higashi
AIM: To investigate near-infrared photoimmunotherapeutic effect mediated by an anti-tissue factor (TF) antibody conjugated to indocyanine green (ICG) in a pancreatic cancer model. METHODS: Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that utilizes an antibody-photosensitizer conjugate administration, followed by NIR light exposure. Anti-TF antibody 1849-ICG conjugate was synthesized by labeling of rat IgG2b anti-TF monoclonal antibody 1849 (anti-TF 1849) to a NIR photosensitizer, ICG...
December 28, 2018: World Journal of Gastroenterology: WJG
Kazuhide Sato, Kanta Ando, Shuhei Okuyama, Shiho Moriguchi, Tairo Ogura, Shinichiro Totoki, Hirofumi Hanaoka, Tadanobu Nagaya, Ryohei Kokawa, Hideo Takakura, Masayuki Nishimura, Yoshinori Hasegawa, Peter L Choyke, Mikako Ogawa, Hisataka Kobayashi
Photochemical reactions can dramatically alter physical characteristics of reacted molecules. In this study, we demonstrate that near-infrared (NIR) light induces an axial ligand-releasing reaction, which dramatically alters hydrophilicity of a silicon phthalocyanine derivative (IR700) dye leading to a change in the shape of the conjugate and its propensity to aggregate in aqueous solution. This photochemical reaction is proposed as a major mechanism of cell death induced by NIR photoimmunotherapy (NIR-PIT), which was recently developed as a molecularly targeted cancer therapy...
November 28, 2018: ACS Central Science
Wenquan Ou, Liyuan Jiang, Raj Kumar Thapa, Zar Chi Soe, Kishwor Poudel, Jae-Hoon Chang, Sae Kwang Ku, Han-Gon Choi, Chul Soon Yong, Jong Oh Kim
The efficacy of combined near-infrared (NIR) and immune therapies for inhibiting tumor growth and recurrence has gained increasing research attention. Regulatory T cells in the tumor microenvironment constitute a major obstacle in achieving robust CD8+ T cell antitumor immunotherapy. In the present study, we designed a photoimmunotherapy-based strategy involving a combination of photothermal and photodynamic therapies, followed by Treg cell suppression, for eliciting an immune response with IR-780- and imatinib-loaded layer-by-layer hybrid nanoparticles...
2018: Theranostics
Tadanobu Nagaya, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Peter L Choyke, Hisataka Kobayashi
BACKGROUND: Peritoneal dissemination (PD) of abdominal malignancies is a common form of metastasis and its presence signals a poor prognosis. New treatment is required for patients with PD. Near infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate (APC). In this study, we investigate in vitro and in vivo efficacy of trastuzumab (tra)-IR700DX NIR-PIT on a human epidermal growth factor receptor type 2 (HER2)-positive gastric cancer cell line...
August 31, 2018: Gastric Cancer
Verónica Almeida-Marrero, Eveline van de Winckel, Eduardo Anaya-Plaza, Tomás Torres, Andrés de la Escosura
The development of photoactive and biocompatible nanomaterials is a current major challenge of materials science and nanotechnology, as they will contribute to promoting current and future biomedical applications. A growing strategy in this direction consists of using biologically inspired hybrid materials to maintain or even enhance the optical properties of chromophores and fluorophores in biological media. Within this area, porphyrinoids constitute the most important family of organic photosensitizers. The following extensive review will cover their incorporation into different kinds of photosensitizing biohybrid materials, as a fundamental research effort toward the management of light for biomedical use, including technologies such as photochemical internalization (PCI), photoimmunotherapy (PIT), and theranostic combinations of fluorescence imaging and photodynamic therapy (PDT) or photodynamic inactivation (PDI) of microorganisms...
October 1, 2018: Chemical Society Reviews
Reema Railkar, Piyush K Agarwal
There are limited treatment options for patients with recurrent non-muscle-invasive bladder cancer. In this report, we will talk about the history of photodynamic therapy; although it showed encouraging therapeutic results, it was largely abandoned due to toxicity or bystander effects on normal cells. Monoclonal antibody-conjugates represent an emerging therapeutic approach for malignancies that improves upon tumor specificity. The use of a monoclonal antibody-photosensitizer conjugate is a more selective method of delivering light therapy and has been termed "photoimmunotherapy", which we will discuss in the last part of this report...
July 2018: European Urology Focus
Yuya Isoda, Wen Piao, Eri Taguchi, Junko Iwano, Shigeki Takaoka, Aiko Uchida, Kiyomi Yoshikawa, Junichi Enokizono, Emi Arakawa, Kazuma Tomizuka, Yasuhisa Shiraishi, Kazuhiro Masuda
Photodynamic therapy (PDT) utilize a photosensitizing agent and light for cancer therapy. It exerts anti-cancer effect mainly by inducing vascular occlusion at the irradiated site. By controlling the irradiation area, PDT can be used in a tumor-specific manner. However, the non-specific cellular damage in the surrounding normal tissue is still a serious concern. Photoimmunotherapy (PIT) is a new type of targeted cancer therapy that uses an antibody-photon absorber conjugate (APC). The superiority of PIT to PDT is the improved target specificity, thereby reducing the damage to normal tissues...
July 31, 2018: Oncotarget
B Habermeyer, R Guilard
Photodynamic therapy is an innovative approach to treat diverse cancers and diseases that involves the use of photosensitizing agents along with light of an appropriate wavelength to generate cytotoxic reactive oxygen species. Among the collection of potential dye candidates, porphyrinoids (i.e. porphyrins, chlorins, and phthalocyanines) are probably the most promising photosensitizers for PDT applications. This review shows the great potential of these derivatives for their industrial development in the field of health through different applications in photodynamic therapy (PDT), photoimmunotherapy (PIT), ophthalmology, dermatology and photodynamic inactivation (PDI)...
August 15, 2018: Photochemical & Photobiological Sciences
Lu Li, Shiyi Zhou, NingNing Lv, Zipeng Zhen, Tianji Liu, Shi Gao, Jin Xie, Qingjie Ma
Nanoparticles have been widely tested as drug delivery carriers or imaging agents, largely because of their ability to selectively accumulate in tumors through the enhanced permeability and retention (EPR) effect. However, studies show that many tumors afford a less efficient EPR effect and that many nanoparticles are trapped in the perivascular region after extravasation and barely migrate into tumor centers. This is to a large degree attributed to the dense tumor extracellular matrix (ECM), which functions as a physical barrier to prevent efficient nanoparticle extravasation and diffusion...
August 6, 2018: Molecular Pharmaceutics
Huang-Chiao Huang, Michael Pigula, Yanyan Fang, Tayyaba Hasan
The past three decades have witnessed notable advances in establishing photosensitizer-antibody photo-immunoconjugates for photo-immunotherapy and imaging of tumors. Photo-immunotherapy minimizes damage to surrounding healthy tissue when using a cancer-selective photo-immunoconjugate, but requires a threshold intracellular photosensitizer concentration to be effective. Delivery of immunoconjugates to the target cells is often hindered by I) the low photosensitizer-to-antibody ratio of photo-immunoconjugates and II) the limited amount of target molecule presented on the cell surface...
July 1, 2018: Small
Kohei Nakajima, Hideo Takakura, Yoichi Shimizu, Mikako Ogawa
Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer phototherapy modality using an antibody conjugated to a photosensitizer, IRDye700DX. When the conjugate binds to the plasma membrane and is exposed to NIR light, NIR-PIT-treated cells undergo swelling, and target-selective necrotic/immunogenic cell death is induced. However, the cytotoxic mechanism of NIR-PIT has not been elucidated. In order to understand the mechanism, it is important to elucidate how the damage to the plasma membrane induced by NIR light irradiation changes over time...
September 2018: Cancer Science
Kinam Park
No abstract text is available yet for this article.
June 10, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
Wei Peng, Henriette S de Bruijn, Eric Farrell, Mouldy Sioud, Vida Mashayekhi, Sabrina Oliveira, Go M van Dam, Jan L N Roodenburg, Max J H Witjes, Dominic J Robinson
OBJECTIVE: The aim of this study was to investigate the effects of targeted photoimmunotherapy (PIT) in vitro on cell lines with various expression levels of epidermal growth factor receptor (EGFR) using an anti-EGFR targeted conjugate composed of Cetuximab and IR700DX, phthalocyanine dye. MATERIALS AND METHODS: Relative EGFR density and cell binding assay was conducted in three human head & neck cancer cell lines (scc-U2, scc-U8, and OSC19) and one reference cell line A431...
July 2018: Lasers in Surgery and Medicine
Kohei Nakajima, Toshihiro Kimura, Hideo Takakura, Yasuo Yoshikawa, Atsushi Kameda, Takayuki Shindo, Kazuhide Sato, Hisataka Kobayashi, Mikako Ogawa
Purpose: The aim of this study was to develop and assess a novel implantable, wireless-powered, light-emitting diode (LED) for near-infrared photoimmunotherapy (NIR-PIT). NIR-PIT is a recently developed cancer therapy that uses NIR light and antibody-photosensitizer conjugates and is able to induce cancer-specific cell death. Due to limited light penetration depth it is currently unable to treat tumors in deep tissues. Use of implanted LED might potentially overcome this limitation. Results: The wireless LED system was able to emit NIR light up to a distance of 20 cm from the transmitter coil by using low magnetic fields as compliant with limits for use in humans...
April 13, 2018: Oncotarget
Tadanobu Nagaya, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Deborah W Knapp, Sophia N Karagiannis, Judit Fazekas-Singer, Peter L Choyke, Amy K LeBlanc, Erika Jensen-Jarolim, Hisataka Kobayashi
Anti-epidermal growth factor receptor (EGFR) antibody therapy is used in EGFR expressing cancers including lung, colon, head and neck, and bladder cancers, however results have been modest. Near infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate which is activated by NIR light. NIR-PIT is in clinical trials in patients with recurrent head and neck cancers using cetuximab-IR700 as the conjugate. However, its use has otherwise been restricted to mouse models...
April 10, 2018: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"